- Trial phase
- Phase I
- Time to market
- Very distant; the drug is in early Phase I with no publicly reported enrollment or results since the site initiation visit in March 2023. Assuming successful Phase I, Phase II, and Phase III trials, potential approval would be many years away.
- Why 2/10
- No hard dated catalyst is scheduled in the next ~12 months. The drug completed a Phase I site initiation visit in March 2023 at Cedars-Sinai Medical Center for depression in cancer patients, but no subsequent topline readout, PDUFA date, or pivotal trial start has been publicly announced. The program appears to be a very early-stage, low-priority asset within a small-cap company that has multiple other pipeline candidates (ABV-1504, ABV-1505) and is pursuing a spin-off of its BioKey subsidiary.
Watch for any ABVC press release or SEC filing mentioning advancement of ABV-1601 into patient enrollment or a Phase I data readout. The company's near-term value drivers appear to be its later-stage CNS candidates (ABV-1504/ABV-1505 for MDD/ADHD) and the planned BioKey spin-off, not ABV-1601.
Price Chart
Executive Summary
ABV-1601 is an early-stage Phase I drug candidate from ABVC BioPharma (NASDAQ: ABVC), a clinical-stage company focused on botanical-derived therapeutics for CNS, ophthalmology, and oncology. The drug is being studied for treating depression in cancer patients. The only public clinical milestone was a Phase I site initiation visit at Cedars-Sinai Medical Center in March 2023. No patient enrollment, dosing data, or results have been reported since, and no upcoming catalysts are scheduled. ABV-1601 appears to be a minor, early-stage program within a company whose more advanced pipeline (ABV-1504/ABV-1505 for major depressive disorder and ADHD) and corporate restructuring (BioKey spin-off) are the primary value drivers.
How It Works
ABV-1601 is described as a medication for treating depression in cancer patients. Based on ABVC's broader pipeline focus on botanical-derived therapeutics, it is likely a plant-based or natural compound targeting central nervous system (CNS) disorders, but the specific mechanism of action has not been publicly detailed.
Trial Status
The Cedars-Sinai Medical Center IRB approved site participation in November 2022 for a Phase I study of ABV-1601 treating depression in cancer patients. A site initiation visit (SIV) was successfully conducted on March 31, 2023. No subsequent updates on patient enrollment, dosing, or results have been publicly reported as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- No scheduled catalysts identified for ABV-1601 specifically. Watch for any ABVC press release on pipeline advancement, patient enrollment, or Phase I data for ABV-1601.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report